Pliml W, von Arnim T, Hammer C
Medizinische Klinik, Klinikum Innestadt, Ludwig-Maximilians-Universität München.
Clin Investig. 1993 Oct;71(10):770-3. doi: 10.1007/BF00190316.
Ribose has been used successfully in the treatment of ischemic heart disease and muscular enzyme deficiencies, and its administration also facilitates the diagnosis of coronary artery disease by influencing thallium-201 scintigraphy. Concerns about the safety of ribose therapy have been triggered by reports about inhibitory effects of ribose on cell proliferation in vitro. This study examines possible side effects of ribose on human lymphocytes. Unstimulated and mitogen-stimulated human lymphocytes were incubated with ribose concentrations associated with high-dose oral administration, i.e., 3.5 mM, and with two- (7 mM) and tenfold (35 mM) higher concentrations. Cell cultures with matching glucose concentrations served as controls. Incorporation of [3H]thymidine into cells was used to measure cell proliferation. No significant inhibition of human lymphocyte proliferation in vitro was observed in mitogen-stimulated cells. Unstimulated cultures showed significant inhibition only at 35 mM ribose. It is concluded that ribose plasma levels associated with high-dose oral administration do not inhibit human lymphocyte proliferation in vitro. No evidence was found that short-term ribose therapy is harmful to human lymphocytes.
核糖已成功用于治疗缺血性心脏病和肌肉酶缺乏症，并且其给药还通过影响铊-201闪烁扫描术促进冠状动脉疾病的诊断。关于核糖疗法安全性的担忧是由关于核糖在体外对细胞增殖的抑制作用的报道引发的。本研究检测了核糖对人淋巴细胞可能产生的副作用。将未受刺激和经丝裂原刺激的人淋巴细胞与高剂量口服给药相关的核糖浓度（即3.5 mM）以及两倍（7 mM）和十倍（35 mM）更高浓度一起孵育。具有匹配葡萄糖浓度的细胞培养物用作对照。用[3H]胸苷掺入细胞来测量细胞增殖。在经丝裂原刺激的细胞中未观察到体外人淋巴细胞增殖的显著抑制。未受刺激的培养物仅在35 mM核糖时显示出显著抑制。得出的结论是，与高剂量口服给药相关的核糖血浆水平在体外不抑制人淋巴细胞增殖。没有发现证据表明短期核糖疗法对人淋巴细胞有害。
